Novel Strategies for Controlling Persistent Viral Infection

控制持续病毒感染的新策略

基本信息

  • 批准号:
    9077410
  • 负责人:
  • 金额:
    $ 48.13万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-04-01 至 2020-03-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Persistent viral infections represent a significant public health problem with hundreds of millions of people infected. However, therapies that enable the host to purge these infections have been unsuccessful due to a limited understanding of the cellular and molecular mechanisms that promote virus persistence. Over the last decade studies have demonstrated that persistent viruses take advantage of negative immune regulatory molecules (IL-10, PD-1) to suppress the antiviral CD4 and CD8 T cell responses, resulting in T cell exhaustion, enabling virus persistence. Deletion of several immune stimulatory molecules such as IL-6 and IL- 21 result in lifelong virus persistence, suggest that the balance between negative and positive immune regulators determines virus clearance or persistence. Importantly, molecules such as IL-6 and IL-21 have known T follicular helper cell (TFH) and B cell stimulatory capacities and depletion of these molecules in vivo results in reduced TFH, B cell responses and antibody production. In fact, studies in humans have demonstrated that although TFH and germinal center (GC) B cells are generated during human persistent virus infection, their function is impaired. Despite the above findings, the mechanisms that restrain/promote optimal TFH, B and antibody responses during persistent virus infection are incompletely understood. We recently made the unexpected finding that during persistent LCMV infection IFN-I signaling was essential to promoting (rather than preventing) virus persistence. Importantly, IFN-I signaling supported induction of negative immune regulators (NIR) IL-10 and PD-L1, immune suppression, T cell exhaustion and lymphoid tissue destruction. Following up our published studies we now report that blockade of IFN-I signaling results in enhanced TFH, GC and plasma B cell responses. Thus we hypothesize IFN-I signaling restrains antiviral humoral immunity during persistent virus infection. The ultimate goal of this proposal is to generate a detailed understanding how IFN-I signaling modulates immune responses during persistent virus infection. The output of our studies should be a detailed cellular and molecular understanding how IFN-I regulates anti-viral humoral and cellular immune responses during persistent virus infection. In this project will use anti-IFNAR1 neutralizing antibodies, genetic and biochemical tools to determine how IFNAR1 signaling regulates TFH, GC and plasma B cell responses during a model persistent virus infection. This proposal encompasses important basic and potentially translational research goals - 1) to understand the mechanisms by which IFNAR1 signaling suppresses immune cell function; 2) discover IFN-I regulated cellular and biochemical pathways that promote virus persistence; and 3) leverage this knowledge to instruct future development of therapeutic modalities to promote immune responses to control of human persistent viral infection.
 描述(申请人提供):持续的病毒感染是一个重大的公共卫生问题,有数亿人感染。然而,由于对促进病毒持久性的细胞和分子机制的了解有限,使宿主能够清除这些感染的治疗方法一直不成功。过去十年的研究表明,持久性病毒利用负性免疫调节分子(IL-10、PD-1)抑制抗病毒的CD4和CD8 T细胞反应,导致T细胞耗尽,使病毒持续存在。几种免疫刺激分子如IL-6和IL-21的缺失会导致病毒的终生持续,这表明正负免疫调节因子之间的平衡决定了病毒的清除或持续。重要的是,IL-6和IL-21等分子具有已知的T滤泡辅助细胞(TFH)和B细胞刺激能力,体内这些分子的耗尽会导致TFH、B细胞反应和抗体产生的减少。事实上,对人类的研究表明,尽管在人类持续病毒感染期间会产生TFH和生发中心(GC)B细胞,但它们的功能受到了损害。尽管有上述发现,但在持续病毒感染期间抑制/促进最佳TFH、B和抗体反应的机制尚不完全清楚。我们最近有了一个意想不到的发现,在LCMV持续感染期间,干扰素-I信号对于促进(而不是防止)病毒持续是必不可少的。重要的是,干扰素-I信号支持负免疫调节因子(NIR)IL-10和PD-L1的诱导,免疫抑制,T细胞耗竭和淋巴组织破坏。根据我们已发表的研究,我们现在报告,阻断干扰素-I信号会导致TFH、GC和血浆B细胞反应增强。因此,我们假设在持续病毒感染期间,干扰素-I信号抑制了抗病毒体液免疫。 这项建议的最终目标是详细了解干扰素-I信号如何在持续病毒感染期间调节免疫反应。我们研究的成果应该是详细的细胞和分子理解干扰素-I如何在持续病毒感染期间调节抗病毒体液和细胞免疫反应。在这个项目中,将使用抗IFNAR1中和抗体、遗传和生化工具来确定IFNAR1信号如何在模型持续病毒感染期间调节TFH、GC和血浆B细胞反应。这项建议包括重要的基础和潜在的转译研究目标-1)了解IFNAR1信号抑制免疫细胞功能的机制;2)发现干扰素-I调节的促进病毒持久性的细胞和生化途径;以及3)利用这一知识指导未来治疗方法的发展,以促进免疫反应,以控制人类持续性病毒感染。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John Ross Teijaro其他文献

John Ross Teijaro的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('John Ross Teijaro', 18)}}的其他基金

Animal and Organoid Model Core
动物和类器官模型核心
  • 批准号:
    10514322
  • 财政年份:
    2022
  • 资助金额:
    $ 48.13万
  • 项目类别:
The role of IL-27 in sustaining the exhausted CD8 T cell response to persistent infection and cancer.
IL-27 在维持耗尽的 CD8 T 细胞对持续感染和癌症的反应中的作用。
  • 批准号:
    10445313
  • 财政年份:
    2021
  • 资助金额:
    $ 48.13万
  • 项目类别:
The role of IL-27 in sustaining the exhausted CD8 T cell response to persistent infection and cancer.
IL-27 在维持耗尽的 CD8 T 细胞对持续感染和癌症的反应中的作用。
  • 批准号:
    10316578
  • 财政年份:
    2021
  • 资助金额:
    $ 48.13万
  • 项目类别:
The role of IL-27 in sustaining the exhausted CD8 T cell response to persistent infection and cancer.
IL-27 在维持耗尽的 CD8 T 细胞对持续感染和癌症的反应中的作用。
  • 批准号:
    10650747
  • 财政年份:
    2021
  • 资助金额:
    $ 48.13万
  • 项目类别:
Engineer Immune Cells via Chemoenzymatic Glycan Editing
通过化学酶聚糖编辑工程免疫细胞
  • 批准号:
    10350593
  • 财政年份:
    2019
  • 资助金额:
    $ 48.13万
  • 项目类别:
Engineer Immune Cells via Chemoenzymatic Glycan Editing
通过化学酶聚糖编辑工程免疫细胞
  • 批准号:
    10578671
  • 财政年份:
    2019
  • 资助金额:
    $ 48.13万
  • 项目类别:
IL-27 elicited antibodies: A novel means to control persistent Arenavirus infection
IL-27 引发抗体:控制持续性沙粒病毒感染的新方法
  • 批准号:
    9204389
  • 财政年份:
    2016
  • 资助金额:
    $ 48.13万
  • 项目类别:
Novel Strategies for Controlling Persistent Viral Infection
控制持续病毒感染的新策略
  • 批准号:
    9248857
  • 财政年份:
    2016
  • 资助金额:
    $ 48.13万
  • 项目类别:
The Role of IL-27 in Controlling Persistent Viral Infection
IL-27 在控制持续病毒感染中的作用
  • 批准号:
    8897666
  • 财政年份:
    2014
  • 资助金额:
    $ 48.13万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 48.13万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 48.13万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 48.13万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 48.13万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 48.13万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 48.13万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 48.13万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 48.13万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 48.13万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 48.13万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了